Septerna (NASDAQ:SEPN) Insider Samira Shaikhly Sells 11,798 Shares

by · The Cerbat Gem

Septerna, Inc. (NASDAQ:SEPN – Get Free Report) insider Samira Shaikhly sold 11,798 shares of the stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $30.06, for a total value of $354,647.88. Following the completion of the sale, the insider directly owned 793 shares of the company’s stock, valued at $23,837.58. The trade was a 93.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Samira Shaikhly also recently made the following trade(s):

  • On Monday, March 2nd, Samira Shaikhly sold 70,453 shares of Septerna stock. The stock was sold at an average price of $28.10, for a total transaction of $1,979,729.30.

Septerna Stock Up 4.2%

Shares of SEPN stock opened at $31.05 on Friday. The company has a 50 day moving average of $25.36 and a 200-day moving average of $26.06. Septerna, Inc. has a 12-month low of $9.11 and a 12-month high of $32.63. The firm has a market cap of $1.40 billion, a P/E ratio of -38.33 and a beta of 2.21.

Septerna (NASDAQ:SEPN – Get Free Report) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.23. Septerna had a negative return on equity of 12.72% and a negative net margin of 49.88%.The company had revenue of $26.52 million during the quarter, compared to the consensus estimate of $16.98 million. As a group, equities analysts expect that Septerna, Inc. will post -1.57 EPS for the current year.

Institutional Investors Weigh In On Septerna

Several hedge funds have recently added to or reduced their stakes in SEPN. Group One Trading LLC lifted its stake in Septerna by 111.8% during the fourth quarter. Group One Trading LLC now owns 944 shares of the company’s stock worth $26,000 after purchasing an additional 8,955 shares during the last quarter. Global Retirement Partners LLC bought a new stake in Septerna during the fourth quarter worth about $35,000. Russell Investments Group Ltd. bought a new stake in Septerna during the third quarter worth about $36,000. Caitong International Asset Management Co. Ltd bought a new stake in Septerna during the fourth quarter worth about $53,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in Septerna during the fourth quarter worth about $61,000.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Stifel Nicolaus assumed coverage on Septerna in a research report on Friday, May 1st. They set a “buy” rating and a $43.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $60.00 target price on shares of Septerna in a research report on Tuesday, March 10th. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Septerna in a research note on Wednesday, May 13th. JPMorgan Chase & Co. lifted their price target on Septerna from $34.00 to $38.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 24th. Finally, Truist Financial lifted their price target on Septerna from $34.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, March 11th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.13.

View Our Latest Stock Analysis on Septerna

Septerna Company Profile

(Get Free Report)

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.

Featured Stories